Illumina Inc. announced research results showing its newly launched TruPath Genome whole-genome workflow can improve variant detection and long-range phasing, including in difficult-to-map “dark” genomic regions, with DRAGEN algorithms tuned to use proximity information from TruPath flow cells. The company said data demonstrating accuracy in rare genetic disease detection was presented at the AGBT meeting, alongside prior published and preprint reports, including evaluations from University Medical Center Utrecht and the University of Exeter on challenging rare-disease samples and complex structural variants.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.
Comments